NTLA

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

8.940

Open

8.040

VWAP

8.56

Vol

4.23M

Mkt Cap

918.20M

Low

7.9034

Amount

36.17M

EV/EBITDA(TTM)

Total Shares

96.48M

247.33M

EV/OCF(TTM)

P/S(TTM)

14.00

Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

12.06M

+32.37%

-1.143

-14.72%

11.97M

+72.02%

-1.158

-23.83%

11.99M

-58.58%

-1.271

+13.49%

Estimates Revision

The market is revising Downward the revenue expectations for Intellia Therapeutics, Inc. (NTLA) for FY2025, with the revenue forecasts being adjusted by -12.02% over the past three months. During the same period, the stock price has changed by -7.02%.

Revenue Estimates for FY2025

Revise Downward

-12.02%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-7.67%

In Past 3 Month

Stock Price

Go Down

-7.02%

In Past 3 Month

18 Analyst Rating

293.12% Upside

Wall Street analysts forecast NTLA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTLA is 34.87 USD with a low forecast of 9.00 USD and a high forecast of 74.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Buy

4 Hold

1 Sell

Moderate Buy

293.12% Upside

Current: 8.870

Low

9.00

Averages

34.87

High

74.00

293.12% Upside

Current: 8.870

Low

9.00

Averages

34.87

High

74.00

Wolfe Research

Andy Chen

Hold

Buy

Upgrades

$21

2025-04-21

Reason

Wolfe Research

Andy Chen

Price Target

$21

2025-04-21

Upgrades

Hold

Buy

Reason

Wolfe Research upgraded Intellia Therapeutics to Outperform from Peer Perform with a $21 price target.

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Initiates

$30

2025-03-05

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

$30

2025-03-05

Initiates

Strong Buy

Reason

Truist Securities

Joon Lee

Strong Buy

Maintains

$90 → $50

2025-03-04

Reason

Truist Securities

Joon Lee

Price Target

$90 → $50

2025-03-04

Maintains

Strong Buy

Reason

Truist analyst Joon Lee lowered the firm's price target on Intellia Therapeutics to $50 from $90 and keeps a Buy rating on the shares. Intellia's restructuring should help extend the company's operational runway into the first half of 2027, as NTLA-2002 is poised to be the historic first in vivo genome editing therapeutic to launch in 2027 for hereditary angioedema, the analyst tells investors in a research note. While the firm believes Intellia has a winning platform, it says it is headed in an increasingly competitive space, driving the firm to moderate its commercial outlook for nex-z in transthyretin amyloidosis.

JP Morgan

Brian Cheng

Buy

Hold

Downgrades

$45 → $13

2025-02-28

Reason

JP Morgan

Brian Cheng

Price Target

$45 → $13

2025-02-28

Downgrades

Buy

Hold

Reason

Chardan Capital

Geulah Livshits

Strong Buy

Maintains

$91 → $68

2025-02-28

Reason

Chardan Capital

Geulah Livshits

Price Target

$91 → $68

2025-02-28

Maintains

Strong Buy

Reason

Wells Fargo

Yanan Zhu

Buy

Maintains

$60 → $50

2025-02-28

Reason

Wells Fargo

Yanan Zhu

Price Target

$60 → $50

2025-02-28

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Intellia Therapeutics Inc (NTLA.O) is -1.74, compared to its 5-year average forward P/E of -11.73. For a more detailed relative valuation and DCF analysis to assess Intellia Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-11.73

Current PE

-1.74

Overvalued PE

-0.92

Undervalued PE

-22.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-8.90

Current EV/EBITDA

-0.43

Overvalued EV/EBITDA

-0.16

Undervalued EV/EBITDA

-17.64

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

90.49

Current PS

17.82

Overvalued PS

167.14

Undervalued PS

13.83

Financials

Annual

Quarterly

FY2024Q4

YoY :

-771.57%

12.87M

Total Revenue

FY2024Q4

YoY :

-2.46%

-136.45M

Operating Profit

FY2024Q4

YoY :

-2.47%

-128.90M

Net Income after Tax

FY2024Q4

YoY :

-13.01%

-1.27

EPS - Diluted

FY2024Q4

YoY :

-8.88%

-86.18M

Free Cash Flow

FY2024Q4

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2024Q4

YoY :

-45.53%

-612.78

FCF Margin - %

FY2024Q4

YoY :

-24.52%

-1.00K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

6.1K

USD

3-6

Months

736.8K

USD

6-9

Months

38.3K

USD

0-12

Months

46.9K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.1M

Volume

6-9

Months

0.0

Volume

0-12

Months

646.6K

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.2M

Volume

Months

6-9

0.0

Volume

Months

0-12

2.9M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

6.1K

USD

3-6

Months

736.8K

USD

6-9

Months

38.3K

USD

0-12

Months

46.9K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

NTLA News & Events

Events Timeline

2025-04-03 (ET)

2025-04-03

07:31:51

Intellia Therapeutics announces first patient dosed in MAGNITUDE-2 trial

2025-03-31 (ET)

2025-03-31

09:32:22

BMO says Peter Marks resignation 'significant negative' for biotech

2025-03-26 (ET)

2025-03-26

07:32:19

Intellia Therapeutics announces FDA RMAT designation to nex-z

News

5.0

04-26Benzinga

Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms

7.0

04-23PRnewswire

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

9.0

04-22WSJ

Trump’s FDA Sends a Bullish Signal to Biotech

People Also Watch

Entrada Therapeutics Inc

Greene County Bancorp Inc

Rapport Therapeutics Inc

Concrete Pumping Holdings Inc

Ballard Power Systems Inc

RCI Hospitality Holdings Inc

FAQ

What is Intellia Therapeutics Inc (NTLA) stock price today?

The current price of NTLA is 8.87 USD — it has increased 8.17 % in the last trading day.

NTLA

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

NTLA News & Events

Events Timeline

News

People Also Watch

FAQ

What is Intellia Therapeutics Inc (NTLA) stock price today?

What is Intellia Therapeutics Inc (NTLA)'s business?

What is the price predicton of NTLA Stock?

What is Intellia Therapeutics Inc (NTLA)'s revenue for the last quarter?

What is Intellia Therapeutics Inc (NTLA)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Intellia Therapeutics Inc (NTLA)'s fundamentals?

How many employees does Intellia Therapeutics Inc (NTLA). have?

What is Intellia Therapeutics Inc (NTLA) market cap?